Abstract
Get full access to this article
View all access options for this article.
References
1.uniQure . 2017 . uniQure announces it will not seek marketing authorization renewal for Glybera in Europe . Available at: https://globenewswire.com/news-release/2017/04/20/962549/0/en/uniQure-Announces-It-Will-Not-Seek-Marketing-Authorization-Renewal-for-Glybera-in-Europe.html (accessed May 13 , 2017
2.Tocagen . 2017 . Tocagen announces closing of initial public offering and exercise of the underwriters' option . Available at: http://ir.tocagen.com/phoenix.zhtml?c=254300&p=irol-newsArticle&ID=2263001 (accessed May 13 , 2017
3.Tocagen . 2017 . Prospectus filed pursuant to Rule 424(b)(4) . Available at: https://www.sec.gov/Archives/edgar/data/1419041/000119312517123405/d312753d424b4.htm#toc312753_4 (accessed May 13 , 2017
4.Novartis . 2017 . Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL . Available at: www.novartis.com/news/media-releases/novartis-car-t-cell-therapy-ctl019-receives-fda-breakthrough-therapy-designation (accessed May 13 , 2017
5.BioMarin Pharmaceutical . 2017 . FDA approves Brineura™ (cerliponase alfa) for the treatment of CLN2 disease, a form of Batten disease and ultra-rare pediatric brain disorder in children . Available at: http://investors.biomarin.com/2017-04-27-FDA-Approves-Brineura-TM-cerliponase-alfa-for-the-Treatment-of-CLN2-Disease-a-Form-of-Batten-Disease-and-Ultra-Rare-Pediatric-Brain-Disorder-in-Children (accessed May 13 , 2017
6.Audentes Therapeutics . 2017 . Audentes Therapeutics reports first quarter 2017 financial results and provides corporate update . Available at: http://investors.audentestx.com/phoenix.zhtml?c=254280&p=irol-newsArticle&ID=2272244 (accessed May 18 , 2017
7.REGENXBIO . 2017 . REGENXBIO reports first quarter 2017 financial results and recent operational highlights . Available at: http://ir.regenxbio.com/phoenix.zhtml?c=254175&p=RssLanding&cat=news&id=2271483 (accessed May 18 , 2017
8.REGENXBIO . 2017 . Prospectus filed pursuant to Rule 424(b)(5) . Available at: http://services.corporate-ir.net/SEC.Enhanced/SecCapsule.aspx?c=254175&fid=14910459 (accessed May 18 , 2017
9.
Mullin
E
. 2017 . A year after approval, gene-therapy cure gets its first customer . MIT Technology Review , May 3 . Available at: www.technologyreview.com/s/604295/a-year-after-approval-gene-therapy-cure-gets-its-first-customer/ (accessed May 13 , 2017